| 0.0001 0 (0%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 0 | 1-year : | 0 |
| Resists | First : | 0 | Second : | 0 |
| Pivot price | 0 | |||
| Supports | First : | 0 | Second : | 0 |
| MAs | MA(5) : | 0 | MA(20) : | 0 |
| MA(100) : | 0 | MA(250) : | 0  |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 0 | D(3) : | 0 |
| RSI | RSI(14): 0 | |||
| 52-week | High : | 0.01 | Low : | 0 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ UTRS ] has closed Bollinger Bands are 0% narrower than normal.
| If tomorrow: | Open lower | Open higher |
| High: | 0 - 0 | 0 - 0 |
| Low: | 0 - 0 | 0 - 0 |
| Close: | 0 - 0 | 0 - 0 |
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Mon, 18 Dec 2023
Why Is Minerva Surgical (UTRS) Stock Down 50% Today? - InvestorPlace
Fri, 25 Aug 2023
Why Affirm Holdings Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket - markets.businessinsider.com
Thu, 23 Mar 2023
Minerva Surgical names Kaile Zagger chief commercial officer - MassDevice
Thu, 09 Feb 2023
Minerva Surgical closes $30M financing, has new controlling stockholder - MassDevice
Mon, 30 Jan 2023
Why CN Energy Group Shares Are Trading Lower By 47%; Here Are 20 Stocks Moving Premarket By Benzinga - Investing.com UK
Thu, 26 Jan 2023
Minerva Surgical (UTRS) Stock Surged 68.4% on Investor Interest - AskTraders.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
OTC
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 9 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 70 (%) |
| Shares Short | 37 (K) |
| Shares Short P.Month | 2 (K) |
| EPS | -7.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.27 |
| Profit Margin | -64.8 % |
| Operating Margin | -51 % |
| Return on Assets (ttm) | -27.4 % |
| Return on Equity (ttm) | -160.1 % |
| Qtrly Rev. Growth | -5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 5.82 |
| EBITDA (p.s.) | -2.88 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -39 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|